Al-Hasan Mohammed, Rich Nicole E, Figueroa Gloria, Garces Stephanie Marie, Quirk Lisa, Yekkaluri Sruthi, Yopp Adam, Jones Patricia D, Singal Amit G
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Parkland Health, Dallas, Texas, USA.
Hepatol Commun. 2025 Jun 9;9(7). doi: 10.1097/HC9.0000000000000735. eCollection 2025 Jul 1.
Racial and ethnic minority populations are disproportionately impacted by HCC due to more advanced tumor burden and underuse of treatments. We explored racial and ethnic differences in medical mistrust, barriers to treatment, and health literacy among patients with HCC.
We conducted a multicenter survey among patients with newly diagnosed HCC between September 2018 and July 2023 at 4 large U.S. health systems. The survey assessed medical mistrust [Group-Based Medical Mistrust Scale (GBMMS)], health literacy (CHEW Assessment of Health Literacy), and barriers to HCC treatment. We performed multivariable logistic regression to evaluate associations between race and ethnicity and survey measures.
Of 1245 eligible patients, 833 (66.9%) completed the survey (45.9% Hispanic, 35.9% White, and 14.2% Black). A higher proportion of Black and Hispanic patients had high medical mistrust than White patients (14.2% and 3.3% vs. 0.7%, respectively; p<0.001). In multivariable analysis, Black race (OR: 19.2, 95% CI: 4.2-87.7) but not Hispanic ethnicity (OR: 3.72, 95% CI: 0.80-17.2) was significantly associated with high mistrust. Compared to White patients, Black and Hispanic patients both reported greater barriers to HCC treatment, with the most common barriers being concerns about pain (41.6%), financial burden (37.6%), and time commitment (31.1%). Limited health literacy was reported by 38.1% of patients (46.8% Hispanic, 41.0% Black, 26.2% White; p<0.001).
Medical mistrust, barriers to treatment, and limited health literacy are prevalent among Black and Hispanic patients with HCC. Understanding the interplay between race, ethnicity, and these factors is essential to address HCC disparities.
由于肿瘤负担更重以及治疗利用不足,少数族裔人群受肝细胞癌(HCC)的影响尤为严重。我们探讨了HCC患者在医疗不信任、治疗障碍和健康素养方面的种族和民族差异。
2018年9月至2023年7月期间,我们在美国4家大型医疗系统中对新诊断为HCC的患者进行了一项多中心调查。该调查评估了医疗不信任[基于群体的医疗不信任量表(GBMMS)]、健康素养(CHEW健康素养评估)和HCC治疗障碍。我们进行了多变量逻辑回归分析,以评估种族和民族与调查指标之间的关联。
在1245名符合条件的患者中,833名(66.9%)完成了调查(45.9%为西班牙裔,35.9%为白人,14.2%为黑人)。与白人患者相比,黑人和西班牙裔患者中医疗不信任程度高的比例更高(分别为14.2%和3.3%,而白人患者为0.7%;p<0.001)。在多变量分析中,黑人种族(比值比:19.2,95%置信区间:4.2-87.7)而非西班牙裔种族(比值比:3.72,95%置信区间:0.80-17.2)与高度不信任显著相关。与白人患者相比,黑人和西班牙裔患者都报告了更多的HCC治疗障碍,最常见的障碍是对疼痛的担忧(41.6%)、经济负担(37.6%)和时间投入(31.1%)。38.1%的患者报告健康素养有限(西班牙裔为46.8%,黑人为41.0%,白人为26.2%;p<0.001)。
医疗不信任、治疗障碍和健康素养有限在黑人和西班牙裔HCC患者中普遍存在。了解种族、民族与这些因素之间的相互作用对于解决HCC差异至关重要。